Vaccin COVID-19 : L’FDA examine le maintien de l’autorisation

washington – 3 Mai 2024 – L’agence américaine des médicaments, l’FDA, est actuellement en train de réévaluer l’autorisation d’utilisation d’urgence (EUA) du vaccin contre le COVID-19 pour un groupe d’âge spécifique. Cette décision intervient alors que Pfizer demande le maintien de cette autorisation pour les saisons 2025-2026,malgré de faibles taux de vaccination. Des experts de la santé publique,comme Georges Benjamin de l’APHA,craignent que cette réévaluation du vaccin ne crée un vide dans l’offre,particulièrement tardivement dans la saison. L’FDA insiste sur la nécessité d’une évaluation scientifique impartiale et transparente. Découvrez les implications de cette décision cruciale pour la santé publique.

Here’s a breakdown of the key data from the provided text, focusing on the core issue and perspectives:

Main Issue:

The FDA (Food and Drug Administration), under the leadership of Kennedy, is re-evaluating the Emergency Use Authorization (EUA) for the COVID-19 vaccine for a specific age group (not specified in the text). Pfizer is seeking to maintain the EUA for the 2025-2026 season.

Key Perspectives:

FDA (Kennedy): Prioritizes public trust and ensuring recommendations are based on impartial scientific data and a clear process free of conflicts of interest. This suggests a potential review of the data supporting the vaccine’s EUA.
Pfizer: Wants the EUA to remain in place, emphasizing that the vaccine continues to have a favorable safety and efficacy profile. They state the discussions with the FDA are not related to safety or efficacy.
American Public Health Association (Georges Benjamin): Believes removing the EUA would be “inappropriate” and create a gap in vaccine availability, especially late in the season. He acknowledges vaccination rates are low but suggests the FDA’s action would still have a negative impact.

Kennedy (FDA): “The public must know that the recommendations of our health agencies are based on impartial scientific data evaluated by a transparent process and without conflicts of interest.”
Pfizer Spokesperson: “We have requested that the Emergency Use Authorization (EUA) for this age group remain in effect for the 2025-2026 season.”
Georges Benjamin (APHA): “Without a doubt, I would create a gap in vaccine availability and do so late in the season, I think it is clearly inappropriate.”

In essence, the text describes a situation where the FDA is reviewing the EUA for a COVID-19 vaccine, prompting concern from pfizer and public health officials about potential disruptions to vaccine access.